-
HIV/AIDS - Research and Palliative Care
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Profile of darunavir in the management of treatment-experienced HIV patients
(511) Article views
Authors: Cameron Wolfe, Charles Hicks
Published Date September 2009 , Volume 2009:1(Default)
Cameron Wolfe, Charles Hicks
Duke University Medical Center, Division of Infectious Diseases, Durham, NC, USA
Abstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.
Keywords: darunavir, HIV, ritonavir
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
